What kind of drug is Aceminid and what is its market status?

Asciminib (Asciminib, trade name Scemblix) is an innovative drug mainly used to treat chronic myelogenous leukemia (CML). It is a tyrosine kinase inhibitor (TKI) that uses a specific mechanism to reduce the number of malignant leukemia cells in the body to achieve a therapeutic effect. Specifically, aximini inhibits the STAMP pocket of the BCR-ABL1 fusion protein, thereby exerting its anti-cancer effects.

In terms of clinical application, Aceminib has shown obvious efficacy. Studies have shown that a considerable number of patients treated with this drug achieved a major molecular response (MMR), that is, a significant reduction in the number of chronic myelogenous leukemia cells in the body. In addition, the drug's safety and tolerability have been widely recognized. Although some patients may experience mild adverse effects such as fatigue, nausea, and diarrhea, most patients adapt well to this treatment.

Aximini was approved for marketing in 2021. It is the first STAMP targeted therapy drug approved by the FDA. It is especially suitable for adult patients with chronic phase Philadelphia chromosome-positive CML (Ph+ CML-CP) who are ineffective or resistant to at least two tyrosine kinase inhibitor treatments. At the same time, it is also approved for adult patients with T315I mutation. Through its unique mechanism of action, this drug provides a new option for patients with chronic myelogenous leukemia. In 2024, Asiminib also received new approval for adult patients with newly diagnosed chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia.

Although Aceminib has shown good therapeutic effects internationally, it is not currently available in mainland China. Due to this restriction, domestic patients need to purchase Asiminib from overseas, and the price varies depending on the manufacturer and region. For example, the European version of the original drug Aceminid produced by Novartis is priced at more than 40,000 RMB per box (40mg*60 tablets); while the generic drug produced by Lucius Pharmaceuticals in Laos is more affordable, priced at more than 4,000 RMB per box, providing an economic solution for many patients.

In summary, as a new type of drug, aceminib has demonstrated good therapeutic effects and tolerability in the international market. Although it has not yet been approved in the Chinese market, patients can still obtain the drug through formal channels, thus bringing more treatment opportunities and hope to patients with chronic myelogenous leukemia.

References:

https://www.drugs.com/newdrugs/novartis-scemblix-granted-fda-accelerated-approval-newly-diagnosed-cml-6401.html

https://www.drugs.com/newdrugs/fda-approves-scemblix-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia-ph-cml-5705.html